Form 4: Alto Neuroscience Reprices CEO's Stock Options to $2.35 Amidst Market Downturn

Alto Neuroscience, Inc. has repriced stock options for its President and CEO, Amit Etkin, to an exercise price of $2.35 per share, effective July 3, 2025, impacting over 700,000 shares.

Summary

• Alto Neuroscience, Inc. repriced stock options for its President and CEO, Amit Etkin, effective July 3, 2025.
• The new exercise price for these options is $2.35 per share, which was the closing price of the company's common stock on the repricing date.
• The repricing applies to options with original exercise prices greater than $2.35 per share held by continuing employees, including the CEO.
• A total of 719,910 shares underlying various employee stock options held by Amit Etkin were affected by this repricing.
• Original exercise prices for the repriced options ranged from $4.20 to $14.88 per share.
• Vesting schedules, expiration dates, and the number of shares underlying the options remain unchanged.
• A condition requires the original exercise price to be paid if a repriced option is exercised before the end of a one-year retention period, subject to certain earlier termination circumstances.

Sentiment

Score: 4

Explanation: The repricing of stock options, while beneficial for employee retention and motivation, typically signals a significant decline in the company's stock price, which is a negative indicator for shareholders. It suggests that the company's market performance has been worse than anticipated, leading to 'underwater' options. The move is a reactive measure to address past underperformance rather than a proactive positive development.

Positives

• The repricing of stock options to a lower exercise price of $2.35 per share benefits the President and CEO, Amit Etkin, by making his options 'in-the-money' or reducing their 'underwater' status, thereby increasing their potential value and incentive.
• The repricing aims to retain key talent, as it applies to options held by continuing employees, ensuring their continued motivation and alignment with the company's future performance.

Negatives

• The necessity of repricing stock options typically indicates a significant decline in the company's stock price, suggesting underperformance relative to the original grant prices.
• Repricing options can be viewed negatively by existing shareholders as it effectively dilutes their stake or signals a lack of confidence in the stock's ability to recover to previous highs.
• The condition requiring payment of the original exercise price if options are exercised within a one-year retention period adds a layer of complexity and potential restriction for the option holder.

Future Outlook

The document indicates future vesting of stock options for the reporting person, with various installments scheduled monthly or on specific future dates, contingent on continuous service. A one-year retention period applies to the repriced options, during which the original exercise price must be paid if exercised, unless certain earlier termination circumstances apply.

Management Comments

• The transactions reported herein reflect a one-time stock option repricing (the 'Option Repricing') effective on July 3, 2025 (the 'Repricing Date').
• The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.
• Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date.
• However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option.
• There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

Industry Context

Stock option repricing is a common practice in industries where stock prices have experienced significant declines, particularly in sectors like biotechnology or technology, where early-stage companies might face volatile market conditions. It is often implemented to restore the incentive value of employee stock options that have become 'underwater' (i.e., their exercise price is higher than the current market price), thereby helping companies retain key talent and maintain motivation.

Comparison to Industry Standards

• Repricing underwater stock options is a recognized strategy used by companies, particularly in volatile sectors, to re-incentivize employees when the market price of their stock falls below previously granted option exercise prices.
• The specific terms, such as the new exercise price being set at the current market price ($2.35), and the inclusion of a retention period (one year), are common mechanisms employed to balance employee retention with shareholder concerns.
• While the document does not name specific comparable companies or projects, such repricing events have been observed across various industries, including biotech and tech, when companies like Alto Neuroscience face challenges in maintaining stock value.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially negative impact due to the implied poor stock performance that necessitated the repricing, and the potential for future dilution if the repriced options are exercised at a lower price.
• Employees (specifically Amit Etkin and other continuing employees): Positive impact as their stock options are re-incentivized, making them more valuable and restoring their potential for financial gain, thereby aiding retention.

Next Steps

• Continued vesting of the repriced stock options for Amit Etkin according to their respective schedules (e.g., monthly installments, or specific future dates like February 5, 2026).
• Potential exercise of the repriced options by Amit Etkin, subject to vesting and the one-year retention period condition.

Key Dates

Keywords

Stock Option Repricing, SEC Form 4, Insider Transaction, Employee Stock Options, Executive Compensation, Alto Neuroscience, ANRO, Beneficial Ownership, Equity Compensation, CEO Compensation